Lipella Pharmaceuticals shares were up 37% to $4.18 after the company said it saw positive topline results from its Phase 2a dose-ranging trial examining LP-310, a liposomal-tacrolimus oral rinse ...
About LP-310 LP-310 is an innovative oral rinse formulation of LP-10 (tacrolimus), developed to address OLP. Designed to provide localized therapeutic effects while minimizing systemic exposure, ...
Topical ABT-263 effectively reduced several senescence markers in aged skin, preparing it for improved wound healing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback